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We investigated the eﬀect of LPS in vitro stimulation on T-cell activation in HIV-infected patients with diﬀerent CD4+ recovery
on HAART. PBMCs from 30 HIV-positive, HAART-treated, aviremic individuals with diﬀerent CD4+ reconstitution (Low
Responders: CD4+ < 350/µL; Intermediate Responders: CD4+ 350–599/µL; High Responders: CD4+ ≥ 600/µL) were cultured
with LPS and the proportion of HLA-DR/CD38- and Ki67-expressing CD4+/CD8+ T-cells was measured (ﬂow cytometry). Upon
LPS stimulation, signiﬁcantly higher CD4+ and CD8+HLA-DR+ cells were shown in LR and IR versus HIV-negative controls.
While no diﬀerences in the proportion of LPS-stimulated CD4+CD38+ cells were recorded amongst HIV-positive subgroups,
CD8+CD38+ cells were more elevated in patients with lower CD4+ recovery on HAART (i.e., LR and IR). Upon in vitro LPS
stimulation, HLA-DR and CD38 expression on T-cells are diﬀerentially regulated. While HLA-DR induction reﬂects impaired
CD4+ reconstitution on HAART, cell-surface CD38 expression is increased only on CD8+ T-cells, allowing to speculate that the
sole induction of CD38 on CD4+ cells may not be suﬃcient to depict LPS-driven immune activation in HIV.
1.Introduction
Untreated HIV disease is characterized by high levels of T-
cell activation which account for the progressive depletion of
CD4+ T-cells [1, 2].
Microbial translocation, which occurs following the
breakdown of the gastrointestinal barrier, has been put
forward as a possible mechanism underlying immune acti-
vation in HIV disease [2, 3]. Most interestingly, microbial
translocation-induced T-cell hyperactivation may also repre-
sent a cause of impaired immune restoration on virologically
suppressive HAART [4–6], as suggested by high levels of
circulating lipopolysaccharide (LPS) in patients with poor
CD4+ T-cell recovery in course of eﬀective treatment [4].
In keeping with these observations, in vitro exposure
of PBMCs to LPS and other Toll-Like Receptor (TLR)
agonists has been shown to induce the expression of CD38,
indicator of T-cell activation, on CD4+ and CD8+ T-cells
in healthy individuals [7], thus suggesting a model for HIV
pathogenesis. Indeed, CD38 upregulation on CD8+ cells has
been consistently described in HIV infection and correlates
with disease progression better than HIV RNA load [8–
11]; conversely, the issue of whether high CD38 expression
on CD4+ T-cells is a marker of poor prognosis [8, 9, 11,
12] has been debated for some time [13]. Taken together,
these ﬁndings imply that the actual biological signiﬁcance
of CD38 in the context of HIV/AIDS remains elusive,
given the multiple functions it retains [14]. Indeed, along
with its association with T-cell activation, recent data have
demonstrated that CD38 on CD4+ cells may also identify a
hypoproliferating cell subset, thus oﬀsetting the paradigm of
CD38 as T-cell activation marker [13, 15].
In the light of these premises, we investigated the
dynamics of HLA-DR and CD38 expression on peripheral T-
cells following selective in vitro LPS stimulation of PBMCs
from HIV-infected HAART-treated individuals. We hypoth-
esized that LPS may account for diverse levels of immune
activation in HIV-infected patients according to the degree2 Clinical and Developmental Immunology
of immunological recovery in course of suppressive HAART.
We also hypothesized that HLA-DR and CD38 may not
be equivalent in reﬂecting the extent of T-cell activation
following in vitro stimulation with LPS in the setting of HIV
disease.
2.MaterialsandMethods
2.1. Patients. HIV-positive, HAART-treated patients for
at least 12 months, with undetectable HIV RNA load
(<40cp/mL) and a CD4+ T-cell nadir <250/µL, were consec-
utively enrolled at the Clinic of Infectious Diseases and Trop-
ical Medicine, “San Paolo” Hospital, University of Milan,
Italy. Patients were divided into 3 groups according to the
degree of immune-reconstitution in course of HAART: high
responders (HRs) with CD4+ ≥600/µL, and low responders
(LRs) with CD4+ <350/µL; intermediate responders (IR)
with CD4+ 350–599/µL. As controls, HIV-negative age-
matched subjects were studied. Written informed consent
forms approved by the Ethical Committee of the “San Paolo”
Hospital, University of Milan, Italy, were obtained from all
participants.
2.2. Laboratory Methods
2.2.1. Plasma HIV RNA Levels. Plasma HIV-1 RNA levels
were quantiﬁed by means of a nucleic acid signal ampliﬁca-
tion assay (Abbott Real-Time PCR assay), which has a lower
detection limit of 40 HIV RNA copies/mL of plasma.
2.2.2. Lymphocyte Immunophenotype Analysis. Fresh periph-
eral blood was drawn from all study participants in EDTA-
containing tubes and PBMCs were separated by Ficoll-
Histopaque technique (Biocoll separating solution, BIOSPA)
(T0). Cells were counted and 5×106 cells were cultured in
R10 medium alone (composition per 100mL R10: 88mL
RPMI, 10mL fetal bovine serum, 1mL [100UI/mL] L-
glutamine, and 1mL [100UI/mL] penicillin/streptomycin;
Euroclone, Italy) (unstimulated, US) or in medium supple-
mented with LPS for 24 hours (T1) and 48 hours (T2) (E.
coli;026:B6∗C,Sigma-Aldrich,Milan,Italy,20ng/mL;stim-
ulated, STIM). Prior to and following stimulation, cells were
recounted and stained (CD4+/CD8-PerCP Cy5.5, HLA-DR-
FITC, CD38-PE; Ki67-FITC, Becton Dickinson, San Jos` e,
C A ,U S A )f o rﬂ o wc y t o m e t r i ca n a l y s i so fH L A - D R ,C D 3 8 ,
and Ki67 expression on T-cells (Cytomics FC500, Beckman
Coulter, Hialeah, FL, USA) using CXP 2.2. software.
2.3. Statistics. Data were analyzed with GraphPad 5
PRISMsoftware.Mann-WhitneyU-test,Kruskall-Wallisand
Wilcoxon tests were used for statistics. All statistical tests
were 2-sided and diﬀerences were considered statistically
signiﬁcant at P<0.05.
3. Results
3.1. Patients. 30 HIV-positive, HAART-treated patients with
undetectable HIV RNA load were enrolled. According to the
degreeofimmune-reconstitutiononHAART,9HIV-positive
patients were HR (CD4+ ≥600/µL), 9 resulted LR (CD4+
<350/µL), and 12 intermediate IR CD4+ 350–599/µL. 15
HIV-negative age-matched subjects were also studied.
Duration of HIV infection was comparable in all subjects
(LR: 7 months, IQR 5–19; IR: 13 months, IQR 8–22; HR: 12
months, IQR 6–23; P>0.05 for all comparisons; Table 1).
All patients were on HAART for at least 12 months prior to
evaluation, with no diﬀerences in terms of HAART duration
(LR: 71 months, IQR 46–141; IR: 106 months, IQR 65–149;
HR 71 months, IQR 39–132; P>0.05 for all comparisons;
Table 1) and drug regimen (Table 1).
HRs were signiﬁcantly younger compared to LRs (HR:
39 years, IQR 35–44; LR: 50 years, IQR 45–56; P = 0.02;
Table 1)andpresentedhigherabsoluteCD4+T-cellcountsas
deﬁned by inclusion criteria (LR: 260/µL, IQR 215–339; IR:
498/µL, IQR 425–537; HR: 726/µL, IQR 608–863; P<0.01
for all comparisons; Table 1). A trend to lower CD4+ T-
cell nadir was found in patients with less eﬃcient immune-
reconstitution, (LR: 90/µL, IQR 51–179; IR: 105/µL, IQR 45–
208; HR: 204/µL, IQR 56–240; P>0.05 for all comparisons)
reaching statistical signiﬁcance for percentage values in LR
versus HR (LR: 8%, IQR 5–17; HR: 26%, IQR 22–30; P =
0.03; Table 1).
No other signiﬁcant diﬀerences in demographic and
HIV-related parameters were observed among groups
(Table 1).
3.2. Lymphocyte Immunophenotype Analysis
3.2.1. HLA-DR Expression on CD4+ and CD8+ T-Cells upon
LPS Stimulation. At T0, HIV-positive patients displayed a
tendency to higher HLA-DR+CD4+/CD8+ compared to
controls, reaching signiﬁcance for the CD4+ T-cell subpop-
ulation (CD4+: 30%, IQR 20–54 versus 19%, IQR 5–28; P =
0.02; Figure 1(a); CD8+: 32%, IQR 18–50 versus 21% IQR
11–39; P = 0.07; Figure 1(c)), with no diﬀerences according
to immune-reconstitution (Figures 1(b), and 1(d)).
At T1, following LPS stimulation, HIV-infected individ-
uals as a whole displayed a non-signiﬁcant trend to increased
HLA-DR+CD4+ (19%, IQR 14–33 versus 13%, IQR 11–
26; P = 0.08; Figure 1(e)) and HLA-DR+CD8+ (23%,
IQR 17–37 versus 18%, IQR 13–29 P = 0.2; Figure 1(g))
when compared to healthy controls. Interestingly, when
analysing patients according to CD4+ recovery on HAART,
LPS stimulation resulted in signiﬁcant upregulation of HLA-
DR on CD4+ T-cells in LR (32%, IQR 19–50) compared
to HR (15%, IQR 11–21; P = 0.03; Figure 1(f)) and
controls(P = 0.03;Figure 1(f)).Conversely,nodiﬀerencesin
HLA-DR-expressing proportions upon LPS stimulation were
observed in the CD8+ compartment at this timepoint (LR:
28%, IQR 16–50; IR: 24%, IQR 18–50; HR: 18%, IQR 15–32;
P>0.05 for all comparisons; Figure 1(h)).
At T2, HIV-positive subjects displayed signiﬁcantly
higher LPS-induced HLA-DR+CD4+ (24%, IQR 14–44.3
versus 12%, IQR 8–23; P = 0.006; (i)) and HLA-DR+CD8+
cells (26%, IQR 18–34 versus 13%, IQR 7–25; P =
0.005; (k)). Following stimulation with LPS, a CD4+ T-
cell activation hierarchy was maintained in LR (32%, IQRClinical and Developmental Immunology 3
Table 1: Demographic characteristics and viro-immunological parameters of the patients in study.
Characteristic LR
(n = 9)
IR
(n = 12)
HR
(n = 9)
Age, years (IQR) 50 (45–56) 48 (38–60) 39 (35–44)a
Sex, F (%) 2 (22) 3 (25) 3 (33)
Risk factors for HIV infection
MSM, n (%)
heterosexual, n (%)
IDU, n (%)
2 (22)
6 (67)
1 (11)
5 (42)
4 (33)
3 (25)
1 (11)
3 (33)
5 (56)
Duration of HIV infection, years (IQR) 7 (5–19) 13 (8–22) 12 (6–23)
HAART duration, months (IQR) 71 (46–141) 106 (65–149) 71 (39–132)
Diagnosis of AIDS, n 432
Absolute T CD4+ cell counts, cell/µL( I Q R )
at the time of study
nadir
260 (215–339)
90 (51–179)
498 (425–537)
105 (45–208)
726 (608–863)a
204 (56–240)
Percentage T CD4+ cell counts, % (IQR)
at the time of study
nadir
26 (16–34)
8 (5–17)
27 (22–33)
18 (13–22)
31 (25–43)
26 (22–30)
Plasma HIV RNA, log10cp/mL (IQR)
zenith
at the time of study
5.3 (4.5–5.9)
1.7
5.4 (4.1–5.7)
1.7
4.4 (3.9–5.2)
1.7
HAART regimen
Number of patients at the time of study
NRTI+PI
NRTI+NNRTI
Other
5
2
2
7
4
1
4
3
2
Data are presented as median and interquartile range (IQR). LR: Low Responders (CD4+ < 350/µL, HIV RNA < 40cp/mL); IR: Intermediate Responders
(CD4+ 350–599/µL, HIV RNA < 40cp/mL); HR: High Responders (CD4+ ≥ 600/µL, HIV RNA < 40cp/mL); MSM: Men having sex with men; IDU:
Intravenous Drug Users; HAART: highly active antiretroviral therapy; NRTI: nucleoside reverse-transcriptase inhibitor; NNRTI: nonnucleoside reverse-
transcriptase inhibitor; PI: protease inhibitor. aP<0.05 for diﬀerences among groups.
15–40) and IR (28%, 14–48) over HR (21%, IQR 13–37;
P = 0.4; P = 0.5, resp.; (j)), reaching statistical signiﬁcance
in comparison with HIV-negative controls (P = 0.02 and
P = 0.03, resp.; (j)). Similar results were observed in terms
of LPS-induced expression of HLA-DR on CD8+ cells, with
increased levels in LR (28%, IQR 22–45) and IR (28%, IQR
15–33; (l)) compared to controls (P = 0.007 and P = 0.05)
(l).
A graphical time-course representation of the eﬀect of
LPS stimulation on HLA-DR in HIV-infected individuals
with diﬀerent response to HAART and in HIV-negative
controls is summarized in Figure 3.
3.2.2. CD38 Expression on CD4+ and CD8+ T-Cells upon LPS
Stimulation. Baseline (T0) CD38+CD4+ cells were com-
parable in HIV-positive and HIV-negative patients (66%,
IQR 58–80 versus 66%, IQR 54–75, P = 0.4; Figure 2(a)).
Conversely, CD38+CD8+ cells were higher in HIV-positive
patients (55%, IQR 38–71 versus 38%, IQR 30–59, P = 0.05;
Figure 2(c)). In both cases, no diﬀerences amongst HIV-
infected subgroups were detected (Figures 2(b), and 2(d)).
Mostinterestingly,cellsfromHIV-infectedpatientsfailed
to respond to LPS stimulation at T1, displaying signiﬁcantly
lower proportions of CD38+CD4+ (64%, IQR 55–72.7
versus 73%, IQR 70–82; P = 0.02; Figure 2(e)) and
CD38+CD8+ (54%, IQR 39–67 versus 65%, IQR 55–70,
P = 0.05; Figure 2(g)) compared to HIV-negative controls.
However, within HIV-infected subjects, LR and IR showed
higher CD38+CD8+ (65%, IQR 48–70 and 56%, IQR 45–
71, resp.) compared to HR upon LPS stimulation (41%,
IQR 25–55; P = 0.04 for both comparisons; Figure 2(h)),
while CD38+CD4+ cells did not vary according to immune-
reconstitution (LR: 64%, IQR 55–78; IR: 62%, IQR 55–
75; HR: 64%, IQR 51–67; P>0.05 for all comparisons;
Figure 2(f)).
At T2, HIV-positive and healthy individuals displayed
comparable CD38+CD4+ and CD8+ following LPS stimu-
lation (74%, IQR 65–80 versus 66%, IQR 61–77; P = 0.3;
Figure 2(i); 64%, IQR 50–70 versus 52%, IQR 42–63; P =
0.2; Figure 2(k)). similar to T1 data, LR presented higher
CD38+CD8+ than HR (66%, IQR 64–74 versus 49%, IQR
30–64, P = 0.01 Figure 2(l)) and controls (P = 0.02;
Figure 2(l)), whereas no diﬀerences in CD38+CD4+ cells
were noted amongst HIV-positive subgroups (LR: 74%, IQR
68–78; IR: 79%, IQR 71–83; HR: 60%, IQR 50–77; P>0.05
for all comparisons; Figure 2(j)).
A graphical time-course representation of the eﬀect of
LPS stimulation on CD38 in HIV-infected individuals with
diﬀerent response to HAART and in HIV-negative controls
is summarized in Figure 3.4 Clinical and Developmental Immunology
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Figure 1: HLA-DR-expressing CD4+/CD8+ T-cells in HIV-negative and HIV-positive patients prior to and following LPS stimulation.
HLA-DR expression was measured on freshly ﬁcoll-separated CD4+ and CD8+ T-cells at baseline (T0, top), and following 24- (T1, middle)
and 48-hour (T2, bottom) LPS stimulation. PBMCs were cultured in medium alone (unstimulated, US) or in medium with 20ng/mL LPS
(stimulated, STIM). At T0, HIV-positive individuals displayed higher HLA-DR+CD4+ (P = 0.02, (a)) and HLA-DR+CD8+ proportions
(c), with no diﬀerences amongst HIV-positive subgroups ((b) and (d)). At T1, HIV-positive patients maintained increased HLA-DR+CD4+
(e) and CD8+ cells (g); signiﬁcantly higher HLA-DR+CD4+ levels were detected in LR versus HR and negative controls (P = 0.03 for both
comparisons,(f)).AtT2,HIV-infectedindividualsdisplayedsigniﬁcantlyhigherHLA-DR+CD4+(P = 0.006,(i))andCD8+cellscompared
to controls (P = 0.005, (k)). Following stimulation, signiﬁcantly greater proportions of HLA-DR-expressing CD4+ were measured in LR
(P = 0.02, (j)) and IR (P = 0.03, (j)) compared to controls. Comparable results were detected in the CD8+ compartment upon LPS
stimulation (LR versus HIV-negative, P = 0.007, (l); IR versus HIV-negative, P = 0.05, (l)). P values in the results section refer to stimulated
samples only.
3.2.3. HLA- DR/CD38 Co-expression on CD4+ and CD8+
T-Cells upon LPS Stimulation. At T0 comparable HLA-
DR+CD38+CD4+ cells were observed in HIV-negative
(15.4%, IQR 2.1–25.9) and HIV-positive patients (23.5%,
IQR 7.2–48.8; P = 0.08) with no diﬀerences among HIV
subgroups(LR:20.2%,IQR6.9–42;IR:24.5%,IQR8.1–63.1;
HR: 41.5%, IQR 12.1–49.5; P>0.05 for all comparisons).
At T1, LPS did not account for signiﬁcant changes in
HLA-DR/CD38 coexpression on CD4+ T-cells compared to
baseline values.
Ac o m p l e t e l yd i ﬀerent scenario was pictured upon
LPS stimulation at T2, with signiﬁcantly higher HLADR+
CD38+CD4+ in HIV-positive patients as a whole (20.3%,
IQR 12.1–39.4) and in LR subjects (LR: 20.3%, IQR 12.8–
34.4) compared to controls (9.5%, IQR 6.6–19.0; P = 0.04
and P = 0.03, resp.).
Similar results were observed in HLA-DR/CD38 coex-
pression on CD8+ T-cells, given that no diﬀerences among
study groups were detected at T0: HIV-negative: 13.6%, IQR
4.0–24.9; HIV-positive: 18.3%, IQR 12.1–42.2; LR: 17.9%Clinical and Developmental Immunology 5
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Figure 2: CD38-expressing CD4+/CD8+ T-cells in HIV-negative and HIV-positive patients prior to and following LPS stimulation. CD38
expressionwasmeasuredonfreshlyﬁcoll-separatedCD4+andCD8+T-cellsatbaseline(T0,top)andfollowing24-(T1,middle)and48-hour
(T2, bottom) LPS stimulation. PBMCs were cultured in medium alone (unstimulated, US) or in medium with 20ng/mL LPS (stimulated,
STIM). At T0, comparable CD4+CD38+ were detected in HIV-positive patients and controls (a); however, the former displayed markedly
higher CD8+CD38+ (P = 0.05, (c)), with no diﬀerences amongst HIV-positive subgroups. At T1, a signiﬁcantly lower expression of CD38
was detected on CD4+ (P = 0.02, (e)) and CD8+ cells (P = 0.05, (g)) from HIV-positive individuals despite LPS stimulation. While no
diﬀerences in CD4+CD38+ were recorded amongst HIV-positive subgroups (f), CD8+CD38+ cells were signiﬁcantly higher in LR and IR
compared to HR (P = 0.04 for both comparisons, (h). At T2, LR presented highest CD38+CD8+ compared to HR (P = 0.01, (l)) and
controls (P = 0.02, (l)) with no diﬀerences in CD4+CD38+ (j). P values in the results section refer to stimulated samples only.
IQR 12.2–28.7; IR: 14.1%, IQR 8.0–45.7; HR: 30.5%, IQR
12.8–46.7 (P>0.05 for all comparisons).
While LPS stimulation did not lead to signiﬁcant dif-
ferences in terms of HLA-DR/CD38 induction on CD8+
cells at T1, signiﬁcantly higher HLADR+CD38+CD8+ cells
were detected in HIV-positive patients compared to controls
(20.5%, IQR 10.5–29.0 versus 8.7%, IQR 4.9–20.1; P = 0.02)
at T2.
When examining patients with diﬀerent degree of im-
mune-reconstitution, LR maintained activation CD8+ acti-
vation hierarchy over HIV-negative individuals, with signif-
icantly more HLADR+CD38+CD8+ cells (LR: 24%, IQR
14.6–36.4; P = 0.02).
3.2.4. Ki67 Expression on CD4+ and CD8+ T-Cells upon LPS
Stimulation. At T0, no diﬀerences between HIV-negative
controls and HIV-positive subjects were measured in Ki67
expression on CD4+ (8.2%, IQR 4.0–17.2 versus 12.7%, IQR
2.6–18.2, res.; P = 0.7; Figure 4(a)) and CD8+ T-cells (1.9%,
IQR 0.1–3.7 versus 1.25; IQR 0.0–4.8; P = 0.8; Figure 4(c)).
T-cellproliferationlevelsdidnotvaryaccordingtothedegree
ofimmune-reconstitutionincourseofHAART,despitetrend
to higher Ki67 expression on CD4+ T-cells in HR (17%, IQR6 Clinical and Developmental Immunology
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Figure 3: Time course representation of the eﬀect of LPS on HLA-DR and CD38 expression on CD4+ and CD8+ T-cells. Median HLA-DR
((a) and (b)) and CD38 ((c) and (d)) expression on CD4+ and CD8+ T-cells in HIV-positive and HIV-negative individuals (left portion of
graphs) and in HIV-infected subjects with diﬀerent immunological outcome in course of HAART (right portion of graphs) at baseline (T0)
and following LPS stimulation (T1 stim, T2 stim).
12.6–18.9) compared to LR (5.5%, IQR 1.4–15.5; P = 0.07;
Figure 4(b)).
At T1, LPS stimulation did not account for signiﬁcant
increases in cell proliferation (Figures 4(e)–4(h)). Interest-
ingly, however at T2, a trend to increased Ki67 levels on
CD4+ T-cells upon stimulation was detected in LR (20.5%,
IQR 7.5–31.0) compared to HR (5.5%, IQR 2.0–12.6; P =
0.08) and negative controls (3.9%, IQR 0.4–18.7; P =
0.08; Figure 4(j)), thus mirroring the state of CD4+ T-cell
activation through the expression of HLA-DR (Figure 1(j)).
No diﬀerences were detected in terms of CD8+ T-
cell proliferation among study groups following 48-hour
stimulation with LPS (Figures 4(k), and 4(l)).
4. Discussion
We hereby investigated the induction of CD38, HLA-DR
and Ki67 on CD4+ and CD8+ T-cells following selective in
vitroLPSstimulationinHIV-infectedindividualswithdiﬀer-
ent immunological recovery upon virologically suppressive
HAART.
We enrolled patients on stable antiretroviral therapy
and with comparable demographic and viro-immunological
parameters. Of note, patients with less eﬃcient immune-
reconstitution were signiﬁcantly older and presented
decreasedTCD4+cellnadircomparedtosubjectsdisplaying
sustained CD4+ T-cell recovery; this ﬁnding is in keeping
with literature data demonstrating that age and CD4+ cellClinical and Developmental Immunology 7
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Figure 4: Ki67-expressing CD4+/CD8+ T-cells in HIV-negative and HIV-positive patients prior to and following LPS stimulation. Ki67
expressionwasmeasuredonfreshlyﬁcoll-separatedCD4+andCD8+T-cellsatbaseline(T0,top)andfollowing24-(T1,middle)and48-hour
(T2, bottom) LPS stimulation. PBMCs were cultured in medium alone (unstimulated, US) or in medium with 20ng/mL LPS (stimulated,
S T I M ) .A tT 0 ,n od i ﬀerences between HIV-negative controls and HIV-positive subjects were measured in Ki67 expression on CD4+ (a)
and CD8+ T-cells (c). T-cell proliferation levels did not vary according to the degree of immune-reconstitution in course of HAART ((b)
and(d)).At T1, LPS stimulationdid not account for signiﬁcant increases in cell proliferation ((e)–(h)).At T2, a trend toincreased Ki67 levels
on CD4+ T-cells upon stimulation was detected in LR compared to HR and negative controls (j); no diﬀerences were detected in terms of
Ki67+CD8+ T-cells proliferation among study groups following 48-hour stimulation with LPS ((k) and (l)).
counts at HAART initiation are determinants of incomplete
immunological reconstitution in course of suppressive
HAART [16].
Our data show a diﬀerential eﬀect of LPS in vitro stimu-
lation on the cell-surface expression of two T-cell activation
markers, that is, HLA-DR and CD38: (i) despite an overall
reduction of HLA-DR+ T-cells, patients with an ineﬃcient
response to HAART display a higher proportion of activated
HLA-DR+CD4+/CD8+ compared to individuals with better
CD4+ recovery; (ii) CD38 expression is induced on T-cells,
and yet only the CD38+CD8+ pool is signiﬁcantly expanded
according to the degree of immunological impairment.
HIV infection is characterized by high levels of immune
activation [1, 2] which is a major cause of the progressive
CD4+ T-cell loss in untreated disease [1, 2, 8–10]a n d
impaired immunological recovery in course of HAART
[5, 17]. A possible driver of immune activation is the
translocation of bacterial bioproducts, mainly LPS, through
the gastrointestinal barrier to the systemic circulation [2,
3]. Indeed, literature ﬁndings show that non-progressive
disease in SIV natural host primates associates with no
microbial translocation and/or immune activation [18, 19];
conversely,microbialtranslocationhasbeenindirectlyimpli-
cated in driving immune activation in chronically HIV-
infected humans and SIV-infected Rhesus macaques [19].
In keeping with this model, in HIV-negative individuals,
PBMCsstimulatedinvitrowithLPShavebeendemonstrated
to increase the expression of CD38, and not HLA-DR [7].8 Clinical and Developmental Immunology
Consistent with these ﬁndings and with recent data
showing a dramatic decline in the percentages of DR+
subsets following PBMCs in vitro cultures [20], we hereby
show a reduction of HLA-DR+CD4+/CD8+ cells following
LPS in vitro stimulation in both healthy donors and HIV-
infected individuals. Interestingly enough however, when
evaluating HIV-patients according to the degree of immune
recovery on HAART, while HLA-DR expression was reduced
in patients with good CD4+ recovery, subjects with lower
CD4+ reconstitution, (i.e., LR and IR) maintained stable
HLA-DR-expressingT-cells.Thenetoutcomeofsuchdiverse
eﬀect of LPS stimulation according to the extent of CD4+
recovery, is that subjects with poor immunological recovery
display signiﬁcantly higher HLA-DR+ T-cell proportions. Of
note, LPS accounted for a higher proportion of proliferating
Ki67+ T-cells in the CD4+ subset alone, thus suggesting
that the combined eﬀect of microbial stimulation on T-cell
proliferation and activation seems to be restricted to the
CD4+ cell compartment.
By demonstrating highest LPS-dependant HLA-DR+ T-
cells exclusively in patients with lowest CD4+ recovery, our
ﬁndings add up to the consolidated bulk of evidence on
the inverse correlation between HLA-DR expression and
CD4+ lymphopenia [10, 17]. Thus, HLA-DR might be a
faithful marker of T-cell activation secondary to microbial
translocation in the setting of severe immune impairment.
Ad i ﬀerent trend was shown in CD38-expressing T-cells
upon LPS stimulation.
The time-course analysis of the eﬀect of LPS stimulation
on CD38 expression showed an overall rise in CD38-
expressing T-cellsthat was, however, delayed in HIV-infected
patients compared to healthy controls (i.e., 48 versus 24
hours). Most interestingly, when investigating HIV-positive
subjects with diﬀerent immune recovery separately, only
patients with ineﬃcient CD4+ reconstitution (i.e., LR and
IR) displayed an expansion of the CD38+ T-cell pool,
whereas individuals with good immunological response
(HR) maintained a stable expression of CD38 on T-cells
overtime. Of note, although CD38 appeared selectively
induced on CD4+/CD8+ cells upon longer stimulation,
only CD38+CD8+ cells displayed a linear relationship
with immune impairment on HAART, with LR/IR patients
showing higher LPS-stimulated CD38+CD8+. Conversely,
no diﬀerences in CD38+CD4+ were shown according to the
degree of immune reconstitution.
These ﬁndings are consistent with in vivo data showing
that CD38+CD8+ T-cells are an independent predictor of
disease progression [8–11, 17]; although CD38 has been
described to have a similar prognostic value when expressed
on T CD4+ cells, this seems less consistent [8, 11, 12].
By showing higher LPS-induced expansion of
CD38+CD8+ cells, our ﬁndings suggest a diverse regulation
of CD38 in CD4+ and CD8+ T-cell compartments and
allow to speculate that the sole expression of CD38+ on
CD4+ T-cells may not be suﬃcient to portray the state of
immune activation in HIV disease. Indeed, CD38 has been
shown to be constitutively expressed on phenotypically
na¨ ıve T-cells [13, 15, 21], thus oﬀsetting its role as an
activation marker in the CD4 pool. Indeed, in patients with
impaired immunological recovery in course of HAART,
Massanella et al. recently reported lower proportion
of CD38+CD45RA+CD4+ and higher percentage of
CD38+CD45RA-CD4+ cells, probably reﬂecting a reduced
naive compartment and a higher level of activation in
CD45RA- cells [21]. This ﬁnding is in keeping with data
from Benito et al. [12] who showed that CD38 expression
on CD4+ cells correlated with disease progression when
associated with the expression of phenotypic markers of
m e r m o r y / a c t i v a t e d( C D 4 5 R 0o rH L A - D R ) .
In our study, the co-induction of HLA-DR and CD38
on CD4+ and CD8+ T-cells followed similar kinetics upon
longer (48 hours) stimulation with LPS, with increased
levels of both molecules in subjects with severe immune
impairment on HAART. This ﬁnding, together with the
diﬀerential expression of single cell surface molecules, once
again suggests that CD38 on CD4+ cells may not faithfully
mirror activation in HIV disease.
The present study has several limitations. Our ﬁnding
of an in vitro eﬀect of LPS stimulation in reducing the
expression of activation markers cannot exclude the possi-
bility of increased cellular death following LPS challenge, as
previously shown in HIV-negative patients [7].
Our research was not designed to deﬁne the mechanisms
underlying variable LPS eﬀects and is therefore descriptive
in nature. Functional data on stimulated PBMCs, such as
the production of type I interferons and other cytokines,
would help give a qualitative answer to what activated cells
produce upon microbial challenge. In addition, data on
APC (macrophages, dendritic cells) activation and signalling
following TLR recognition and on the cooperation between
APCs and T-cells would shed light on the precise mecha-
nisms underlying T-lymphocyte activation upon microbial
stimulation.
As a further limitation, we chose to investigate the eﬀect
of LPS alone on T-cell activation. However, given that the
composition of translocating microﬂora may inﬂuence the
immunological response in course of treatment [22], it
would be interesting to study the eﬀect of other stimuli
(e.g., PHA, anti-CD3, PMA) as well as other TLR ligands,
representing microbial components from Gram-positive
bacteria (e.g., Pam3CysK4, TLR1/2 agonist; FSL-1, TLR6/2
agonist) or viral agents (e.g., ssRNA40, TLR8 agonist; CpG
oligonucleotide, TLR9 agonist) on T-cell activation and
response to HAART.
Our results thus advocate further functional studies to
gain deeper insight into the regulation of T-cell activation
by TLR agonists in course of HIV disease and response
to therapy. These data might provide the scientiﬁc back-
ground to investigate/explore alternative/adjuvant therapeu-
tical approaches in HIV infection aimed at manipulating the
negative eﬀects of LPS in inducing immune activation [23].
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